RT Journal Article
SR Electronic
T1 Serum Ferroxidase Activity in Patients with Multiple Sclerosis: A Pilot Study
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1197
OP 1200
VO 28
IS 6
A1 CERVELLATI, CARLO
A1 ROMANI, ARIANNA
A1 FAINARDI, ENRICO
A1 TRENTINI, ALESSANDRO
A1 SQUERZANTI, MONICA
A1 BALDI, ELEONORA
A1 CANIATTI, MARIA LUISA
A1 GRANIERI, ENRICO
A1 BELLINI, TIZIANA
A1 CASTELLAZZI, MASSIMILIANO
YR 2014
UL http://iv.iiarjournals.org/content/28/6/1197.abstract
AB Emerging evidence suggests that oxidative stress might contribute to demyelination and axonal damage in multiple sclerosis (MS). Ferroxidase (FeOx) activity of ceruloplasmin prevents the formation of free radicals from Fe2+ by promoting the incorporation of this pro-oxidant ion to transferrin. The aim of our study was to investigate serum FeOx activity in a cohort of patients with MS and neurological controls. Serum FeOx activity was determined in 69 relapsing-remitting patients with MS and in 62 patients with other inflammatory neurological disorders (OIND) and 52 patients with other non-inflammatory neurological disorders (NIND) as controls. Serum FeOx activity was lower (p<0.01) in MS and OIND than in NIND, without any significant differences among MS patients grouped according to clinical and magnetic resonance evidence of disease activity. A reduced serum FeOx activity, which can potentially lead to a rise in oxidative stress-induced biomolecular damage, seems to be a shared condition in inflammatory disorders of the central nervous system including MS.